15.41
Schlusskurs vom Vortag:
$15.43
Offen:
$15.43
24-Stunden-Volumen:
2.52M
Relative Volume:
1.00
Marktkapitalisierung:
$1.75B
Einnahmen:
$260.81M
Nettoeinkommen (Verlust:
$20.48M
KGV:
118.54
EPS:
0.13
Netto-Cashflow:
$22.67M
1W Leistung:
+0.16%
1M Leistung:
+41.46%
6M Leistung:
+49.56%
1J Leistung:
+20.07%
Dynavax Technologies Corp Stock (DVAX) Company Profile
Firmenname
Dynavax Technologies Corp
Sektor
Telefon
(510) 848-5100
Adresse
2100 POWELL STREET, EMERYVILLE, CA
Vergleichen Sie DVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp
|
15.41 | 1.75B | 260.81M | 20.48M | 22.67M | 0.13 |
|
ZTS
Zoetis Inc
|
125.66 | 57.00B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.90 | 49.88B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.05 | 45.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.39 | 36.84B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
52.72 | 16.33B | 0 | -5.87M | -767.30K | -0.45 |
Dynavax Technologies Corp Stock (DVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Herabstufung | Goldman | Neutral → Sell |
| 2024-02-01 | Eingeleitet | Goldman | Neutral |
| 2022-09-27 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-01-06 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Eingeleitet | Goldman | Buy |
| 2020-08-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-10-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-11 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-02-27 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-05-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-03-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-09-25 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-07-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-07-31 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-05-09 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2016-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-04-27 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-11-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2013-11-25 | Hochstufung | MLV & Co | Hold → Buy |
| 2013-02-25 | Herabstufung | MLV & Co | Buy → Hold |
| 2012-11-16 | Bestätigt | MLV & Co | Buy |
Alle ansehen
Dynavax Technologies Corp Aktie (DVAX) Neueste Nachrichten
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—DVAX, FONR, DBRG, and ONTF - GlobeNewswire Inc.
Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 42% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ - marketscreener.com
Evaluating Dynavax (DVAX) After Its Recent Share Price Rally: Is the Stock Still Undervalued? - simplywall.st
Pacer Advisors Inc. Grows Holdings in Dynavax Technologies Corporation $DVAX - MarketBeat
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies CorporationDVAX - The Malaysian Reserve
Sanofi Acquires Emeryville's Dynavax Technologies for $2.2 Billion, Bolstering Vaccine Portfolio Amid Industry Optimism - Hoodline
Sanofi adds HBV vaccine, shingles candidate via Dynavax takeout: Deals Report - BioCentury
CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies CorporationDVAX - Business Wire
Dynavax (DVAX) rockets 38% on Sanofi $2-billion merger - MSN
Insider Selling: Dynavax Technologies (NASDAQ:DVAX) COO Sells 30,000 Shares of Stock - MarketBeat
Dynavax Technologies (NASDAQ:DVAX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Emeryville's Dynavax accepts $2.2 billion buyout from Sanofi following year of investor pressure - The Business Journals
Dynavax Technologies Signs Agreement and Plan of Merger With Sanofi - TradingView — Track All Markets
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection - GuruFocus
Small Cap Stocks To Keep An Eye OnDecember 25th - MarketBeat
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Insider Monkey
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal - MSN
Exchange Traded Concepts LLC Has $2 Million Stake in Dynavax Technologies Corporation $DVAX - MarketBeat
Dynavax Technologies (NASDAQ:DVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Small Cap Stocks To Follow TodayDecember 24th - MarketBeat
Biggest stock movers Wednesday: DVAX, NKE, INTC, and more - MSN
Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus - Sahm
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday - Benzinga
Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger - Insider Monkey
Assessing Dynavax After a 42% Surge and Strong HEPLISAV B Growth in 2025 - Yahoo Finance
Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why - Benzinga
NKE, OMER, MU, INTC, DVAX: 5 Trending Stocks TodayNike (NYSE:NKE) - Benzinga
Stock Movers: Intel, Dynavax, Snowflake - Bloomberg.com
Why Dynavax Stock Soared Today - Finviz
Sanofi to Buy Dynavax for $2.2 Billion in Cash Deal - USA Herald
Dynavax Stock Climbs: Is It Time to Ride the Wave? - StocksToTrade
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition - MedCity News
European Stocks Close Mixed in Wednesday Trading; Sanofi to Acquire Dynavax Technologies - marketscreener.com
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal By Reuters - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sanofi paying $2.2B for Dynavax; tolebrutinib CRL lands - BioWorld MedTech
Dynavax Technologies Stock Soars on Buyout Buzz - Schaeffer's Investment Research
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio - Yahoo Finance
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion - Yahoo Finance
Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying - Yahoo Finance
Watch Intel Declines; Dynavax Rallies; Nike Ticks Higher - Bloomberg.com
Intel Stock Slides as Nvidia Pauses 18A Testing; Nike Jumps on Tim Cook Buy and Dynavax Soars on Sanofi Deal - ts2.tech
Retail’s Christmas Eve Watchlist: Omeros, Nike, Citi, Dynavax And Agios Spark Most Market Chatter - Stocktwits
Sanofi Buys Dynavax for $2.2 Billion to Boost Vaccine Lineup - Bloomberg.com
Dynavax Technologies stock hits 52-week high at 15.48 USD - Investing.com
Dynavax Technologies stock hits 52-week high at 15.48 USD By Investing.com - Investing.com Canada
Sanofi to Buy Dynavax in $2.2 Billion Cash Deal - marketscreener.com
Sanofi to acquire Dynavax in $2.2B deal to boost adult vaccines - Proactive financial news
Finanzdaten der Dynavax Technologies Corp-Aktie (DVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):